Literature DB >> 9636375

A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2.

K Kawana1, K Matsumoto, H Yoshikawa, Y Taketani, T Kawana, K Yoshiike, T Kanda.   

Abstract

We used human papillomavirus type 16 (HPV-16) particles composed of capsid proteins L1 and L2 (L1/L2 capsids) as an antigen to produce mouse monoclonal antibodies (MAbs). Of 18 MAbs recognizing surface epitopes of L1/L2 capsids, 1 was an anti-L1 MAb and 17 were anti-L2 MAbs. Seven of 11 anti-L2 MAbs recognizing linear epitopes wer found to bind to a synthetic peptide with an HPV-16 L2 sequence of amino acids (aa) 69-81, which is within a highly conserved region among different HPVs. The synthetic peptide reacted with the human sera that had been shown to be positive for an antibody against HPV-16, -18, -58, or -6b capsids composed of L1 alone. The data suggest that the HPV-16 L2 region of aa 69-81 contains a type-common immunodeterminant exposed on the surface of HPV virions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9636375     DOI: 10.1006/viro.1998.9168

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  27 in total

Review 1.  Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications.

Authors:  Allison H Bartlett; Pyong Woo Park
Journal:  Expert Rev Mol Med       Date:  2010-02-01       Impact factor: 5.600

2.  The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle.

Authors:  Sigrid C Holmgren; Nicole A Patterson; Michelle A Ozbun; Paul F Lambert
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  The l2 minor capsid protein of low-risk human papillomavirus type 11 interacts with host nuclear import receptors and viral DNA.

Authors:  J Bordeaux; S Forte; E Harding; M S Darshan; K Klucevsek; J Moroianu
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

4.  Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm.

Authors:  Y Kawana; K Kawana; H Yoshikawa; Y Taketani; K Yoshiike; T Kanda
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

Review 5.  Developments in L2-based human papillomavirus (HPV) vaccines.

Authors:  Christina Schellenbacher; Richard B S Roden; Reinhard Kirnbauer
Journal:  Virus Res       Date:  2016-11-23       Impact factor: 3.303

6.  Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6.

Authors:  K Kawana; H Yoshikawa; Y Taketani; K Yoshiike; T Kanda
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

7.  Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.

Authors:  Monica E Embers; Lynn R Budgeon; Martin Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.

Authors:  Arvind Varsani; Anna-Lise Williamson; Debbie de Villiers; Inga Becker; Neil D Christensen; Edward P Rybicki
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

Review 9.  L2, the minor capsid protein of papillomavirus.

Authors:  Joshua W Wang; Richard B S Roden
Journal:  Virology       Date:  2013-05-17       Impact factor: 3.616

10.  Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Authors:  Subhashini Jagu; Balasubramanyam Karanam; Ratish Gambhira; Sudha V Chivukula; Revathi J Chaganti; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  J Natl Cancer Inst       Date:  2009-05-26       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.